| 英文名稱(chēng) | Pidilizumab (Anti-PDCD1 / PD-1 / CD279) |
|---|---|
| 中文名稱(chēng) | 匹地利珠單抗 |
| CAS號(hào) | 1036730-42-3 |
| 規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
|---|---|---|---|---|
| 1 mg | 3-5days | ¥3600.00 | 登錄后可見(jiàn) | |
| 5 mg | 3-5days | ¥15500.00 | 登錄后可見(jiàn) | |
| 10 mg | 3-5days | ¥28500.00 | 登錄后可見(jiàn) | |
| 50 mg | 3-5days | ¥126000.00 | 登錄后可見(jiàn) | |
| 100 mg | 3-5days | ¥235000.00 | 登錄后可見(jiàn) |
| 英文名稱(chēng) | Pidilizumab (Anti-PDCD1 / PD-1 / CD279) |
|---|---|
| 中文名稱(chēng) | 匹地利珠單抗 |
| CAS號(hào) | 1036730-42-3 |
Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD.